Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biontech Se ADR
(NQ:
BNTX
)
93.01
-2.99 (-3.11%)
Streaming Delayed Price
Updated: 11:54 AM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biontech Se ADR
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
61
62
Next >
BioNTech Stock Gets Upgrade, Analyst Sees Multiple Upside Opportunities
December 15, 2022
Via
Benzinga
Why Is Novavax (NVAX) Stock Plunging Today?
December 15, 2022
NVAX stock is down today on fundraising plans. Here's what investors should know about this once-promising Covid-19 vaccine player.
Via
InvestorPlace
Pfizer Expects $10-$15B From mRNA Vaccine Sales By 2030, Sees $17B Revenues Lost Due To Patent Expiry
December 13, 2022
At Pipeline Day, Pfizer Inc (NYSE: PFE) forecasts annual revenue from its mRNA vaccine portfolio could reach $10-$15 billion by 2030.
Via
Benzinga
Why Merck's $250 Million Investment In Moderna May Have Just Paid Off
December 13, 2022
Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data.
Via
Investor's Business Daily
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
December 09, 2022
From
BioNTech SE
Via
GlobeNewswire
BioNTech, Ryvu Therapeutics Join Forces For Immuno-Modulatory Candidates
November 30, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
December 15, 2022
Via
Benzinga
FDA Authorizes Pfizer/BioNTech And Moderna's Bivalent COVID Shots For 6 Months Old
December 08, 2022
Via
Benzinga
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
December 08, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
December 08, 2022
From
BioNTech SE
Via
GlobeNewswire
US Supports Delay On COVID Patent Waiver Extension Decision
December 06, 2022
Developing countries have been pushing for a patent waiver extension for COVID-19, which many developed countries argue could discourage pharma companies from responding rapidly to future global health...
Via
Benzinga
UK's Regulatory Agency Backs Pfizer/BioNTech's COVID-19 Vaccine For Youngest Kids
December 06, 2022
Via
Benzinga
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
December 06, 2022
Via
Benzinga
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
December 02, 2022
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
December 01, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates
November 30, 2022
From
BioNTech SE
Via
GlobeNewswire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
November 28, 2022
These two companies are facing short-term issues that are likely to give way to long-term success.
Via
The Motley Fool
Is Novavax Stock a Buy Now?
November 26, 2022
There's probably not much good news coming for this biotech in the near future.
Via
The Motley Fool
European Official Says COVID-19 Booster Uptake Disappointing In The Region
November 25, 2022
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather...
Via
Benzinga
Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains
November 25, 2022
Researchers are working on an experimental pan-influenza vaccine based on the famed mRNA technology to provide broad protection.
Via
Benzinga
Is Now the Time for Income Investors to Buy This Big Pharma Stock?
November 24, 2022
This drugmaker is among the most dominant pharmaceutical companies in the world.
Via
The Motley Fool
7 Stocks on the Perfect 10 List
November 23, 2022
Companies that have strong quality, value, or growth grades are the stocks to buy once markets recognize their business potential.
Via
InvestorPlace
PFE Stock Could Be the Booster Shot Your Portfolio Needs Now
November 23, 2022
PFE stock still remains a dirt-cheap dividend darling, even after across-the-board earnings beats and lifted guidance.
Via
InvestorPlace
Jim Cramer Says China's Vaccines 'Don't Work' But Xi Won't Admit It
November 22, 2022
COVID-19 cases have spiked again in China, sparking fresh lockdown measures in the nation's capital. Jim Cramer has suggested that Chinese President Xi Jinping isn't telling the whole story.
Via
Benzinga
2 Reasons to Buy Pfizer and 1 Reason to Sell
November 20, 2022
The pharmaceutical company is looking for a future beyond COVID-19 therapies.
Via
The Motley Fool
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade
November 18, 2022
Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust.
Via
Benzinga
7 Stocks to Sell Right Now… and 1 to Buy
November 18, 2022
Although red ink can sometimes bring an opportunity for contrarianism, these (except one) market ideas represent stocks to sell.
Via
InvestorPlace
Pfizer/BioNTech's Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages
November 18, 2022
Via
Benzinga
Market Rally Holds Key Levels, But Breakouts Struggle; Walmart, Target, Nvidia In Focus: Weekly Review
November 18, 2022
Walmart, Target and Nvidia were key earnings movers.
Via
Investor's Business Daily
Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
November 18, 2022
From
BioNTech SE
Via
GlobeNewswire
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
61
62
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.